Gostner Johanna, PhD

University / Clinic: Department of Internal Medecine
Institute: Division of Haematology and Oncology
 
Research Area: Ep-CAM: human breast cancer therapy

Email: johanna.gostner@i-med.ac.at
Web:  


Research Topic:
In this work stable and inducible EpCAM over-expressing breast cancer cell line models have been established in order to analyze molecular changes in signal transduction. Wnt inhibitors
secreted frizzeled protein 1 (SFRP1) and T cell transcription factor 7 like 2 (TCF7L2) were down-regulated in EpCAM over-expressing cell lines. Futhermore, the TROP2 antigen was analyzed in immunohistochemical studies based on a semiquantitative scoring system for its prognostic value in carcinomas of the breast, pancreas, gastric and oral squamous cell cancer.

Johanna is currently postdoctoral fellow in the division of medical Biochemistry, Medical University Innsbruck, 6020 Innsbruck, Austria



Selected publications:
 
  Gostner J, Fong D, Wrulich O, Lehne F, Zitt M, Hermann M, Krobitsch S, Martowicz A, Gastl G, Spizzo G
Effects of EpCAM overexpression on human breast cancer cell lines.
BMC Cancer. 2011 Jan 31;11:45.

  Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Zitt M, Müller H, Margreiter R, Ofner D, Fong D
TROP2 expression as prognostic marker for gastric carcinoma.
J Clin Pathol. 2009 Feb;62(2):152-8. Epub 2008 Oct

  Fong D, Moser P, Krammel C, Gostner J, Margreiter R, Mitterer M, Gastl G, Spizzo G
High expression of TROP2 correlates with poor prognosis in pancreatic cancer.
Br J Cancer. 2008 Oct 21;99(8):1290-5.

  Fong D, Spizzo G, Gostner J, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M, Laimer K
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity.
Mod Pathol. 2008 Feb;21(2):186-91.